DNA Synthesis Market Size, Share & Trends Analysis Report By Service Type (Gene Synthesis, Oligonucleotide Synthesis), By Length, By Application (Research Development, Diagnostics), By End-use, By Region, And Segment Forecasts, 2024 - 2030

DNA Synthesis Market Size & Trends

The global DNA synthesis market size was estimated at USD 3.13 billion in 2023 and is projected to grow at a CAGR of 15.30% from 2024 to 2030. Market growth can be attributed to the increasing demand for DNA synthesis due to its applications in molecular biology, genetic engineering, and clinical diagnostics & therapeutics. In addition, the growing demand for research in drug discovery and personalized medicine is likely to impact market growth positively over the forecast period.

The COVID-19 pandemic has affected every market globally, and there has been a surge in the demand for efficient treatment. Healthcare providers and pharmaceutical companies were working on discovering the potential usage of oligonucleotides and various genomic expressions to contain the spread of the virus. The pandemic is expected to boost the global market due to an increase in the use of reagents & kits for COVID-19 diagnosis.

DNA synthesis has evolved from a primarily research-focused tool to becoming a cornerstone in clinical diagnostics, offering valuable insights into the genetic underpinning of diseases and contributing to more accurate diagnoses & personalized treatment approaches. DNA synthesis has enabled an understanding of genetic variations that may contribute to an individual's susceptibility to diseases or influence the progression of existing conditions. This is particularly evident in the field of cancer genomics, where DNA synthesis is used to characterize the genomic landscape of tumors, identify driver mutations, and guide targeted therapies.

In addition, the field of synthetic biology focused on the design & construction of biological components and systems for novel applications, relies heavily on custom gene synthesis. The rise of gene therapy and genome editing technologies, such as CRISPR-Cas9, requires custom gene synthesis for designing therapeutic genes, regulatory elements, and gene editing tools. Upon realizing the high potential of genomics in medicine and healthcare, researchers are being encouraged to conduct studies based on artificial gene synthesis. Programs such as the Precision Medicine Initiative, and advancements in companion diagnostic studies have increased the adoption of expression analysis. A high number of expression studies that utilize probes and primers is anticipated to boost the demand for DNA synthesis.

Furthermore, the regulatory environment for genetic research varies from country to country. Many developed and emerging countries recently introduced changes in the regulatory policies related to gene editing and genetic engineering. Identifying the potential applications of genetics in medicine and human health, restrictions on genetic studies have been lifted to allow research for medicine and health. This provides researchers an opportunity to practically implement existing knowledge as well as explore novel approaches.

Market Concentration & Characteristics

Key players are engaged in the launch of new products and services. They are undertaking this strategy to strengthen their product portfolios and offer their customers technologically advanced & innovative products. For instance, in May 2022, GenScript announced the launch of GMP double-strand and single-strand services for supporting cell & gene therapy development.

The market is experiencing a moderate level of merger and acquisition activities by various industry players. This is driven by factors such as the desire to gain a competitive advantage in the industry and the need to consolidate in a rapidly growing market. Companies are also forming collaborations to support research and development in the field of diagnostics and therapeutics. For instance, in April 2023, Twist Bioscience announced a collaboration with Astellas Pharma to support antibody discovery for immunotherapies.

The market is characterized by a significant impact of regulations, with the extent of influence varying depending on the nature and stringency of regulations across different geographical conditions.

Companies are focusing on expanding their service portfolios by launching novel gene synthesis services. For instance, in May 2023, GenScript announced the launch of GenTitan Gene Fragments synthesis service to perform gene synthesis at a relatively low cost. Such launches expedite the expansion of the industry’s services. 

The industry is experiencing moderate regional expansion, driven by a growing customer base for DNA synthesis products and services. As scientific awareness of the technique increases worldwide and access to biotechnology improves in emerging markets, key players in the market are expected to initiate regional expansion initiatives.

Service Type Insights

The oligonucleotide synthesis segment dominated the industry in 2023. The larger share of this segment can be attributed to the focus on genomics research, personalized medicine, and understanding the genetic basis of diseases. Oligonucleotides are essential for molecular biology, genetics, and genomics, supporting applications such as PCR, DNA sequencing, & gene expression studies.

The growing awareness and understanding of genetic disorders contribute to the demand for oligonucleotides in diagnostics & potential therapeutic interventions. For instance, in August 2023, UC San Diego launched a Gene Therapy Initiative to develop innovative treatments for rare diseases, made possible by a USD 5 million donation from the Nancy and Geoffrey Stack Foundation. The initiative seeks to discover novel therapies for children and adults affected by genetic diseases.

The gene synthesis segment is expected to witness the highest CAGR of 16.71% over the forecast period. The gene synthesis is further segmented into custom gene synthesis and gene library synthesis. In gene therapy, new genes are introduced into existing cells to cure or prevent diseases.

Other methods involve regulating mutated genes, using selective reverse mutation by repairing mutated genes, and swapping mutated genes for functional genes. Gene synthesis can be used for cloning synthetic therapeutic genes into custom-made viral vectors for optimizing the expression and enhancing the specificity of gene delivery.

End-use Insights

The biopharmaceutical and diagnostics companies segment dominated the market in 2023 with a market share of 49.53%. Biopharmaceutical companies involved in the market regularly use gene synthesis as an engineering tool to design and produce new DNA sequences & protein functions of interest. Companies involved in this domain include Integrated Biotechnologies, Twist Bioscience, and Codex.

For instance, in May 2021, Twist Bioscience collaborated with GP-write launch a Computer-Aided Design (CAD) platform, which can enable genome building through software. Furthermore, companies involved in developing diagnostics technologies, such as QIAGEN and F. Hoffmann-La Roche Ltd, are witnessing promising growth prospects due to the high demand for effective DNA-based diagnostic tests.

The contract research organizations (CROs) segment is projected to witness the highest CAGR of 17.17% over the forecast period. The growing number of small biotechnology companies and increasing outsourcing trends are expected to influence segment growth. Moreover, contributions by emerging biotechnology companies in the biomedical field are on the rise, owing to increasing funding in the startup ecosystem. This has led to an expansion of the scope of services offered by CROs.

Length Insights

The oligonucleotide synthesis segment dominated the market with the larger revenue share in 2023. The growing awareness and understanding of genetic disorders contribute to the demand for oligonucleotides in diagnostics & potential therapeutic interventions. Short oligonucleotides are used as primers in PCR and qPCR techniques. Researchers often require short, customized oligonucleotides for specific experiments & applications in molecular & cellular biology and other research areas.

Moreover, long oligonucleotides are essential for gene synthesis, allowing the assembly of entire genes or custom DNA constructs. This is crucial in synthetic biology, genetic engineering, and the creation of modified DNA sequences for specific applications. Furthermore, it also plays a key role in synthetic biology, facilitating the design and construction of synthetic genomes or genetic circuits.

The gene synthesis segment is projected to witness the fastest growth at a CAGR of 16.71% from 2024 to 2030. Gene synthesis involves assembling DNA sequences to create custom-designed genes. Advancements in gene synthesis technologies and the growth in complexity of genetic engineering projects further contribute to market growth.

For instance, Eurofins Genomics provides custom gene synthesis services for diagnostic applications, enabling the design of genes for accurate and sensitive diagnostic assays. Moreover, GeneArt Gene Synthesis by Thermo Fisher Scientific offers custom gene synthesis services for metabolic engineering projects, supporting pathway construction.

Application Insights

The research and development segment dominated the market with a share of 63.30% in 2023. This is due to the growing use of DNA synthesis to support ongoing research studies across the globe. Oligonucleotides are essential tools in molecular biology research, genetic testing, and drug development. The process of DNA synthesis holds importance in a variety of research and development fields such as biopharmaceuticals, synthetic biology, gene synthesis, and genome editing.

Moreover, the market is witnessing heightened demand due to the widespread adoption of CRISPR technology. As researchers increasingly employ CRISPR for diverse applications, including gene knockout studies and therapeutic interventions, the industry is experiencing significant growth.

The therapeutics segment is projected to witness the highest CAGR of 16.41% over the forecast period. Nucleotide synthesis is used to consistently support ongoing therapeutic research studies across the globe. Moreover, availability of rapid, accurate DNA synthesis enables faster and effective profiling of a wider range of targets, from the capacity to develop synthetic gene circuits to developing & screening enzymes for therapeutic use. The quest for personalized treatments for numerous genetic illnesses and cancers has pushed therapeutics to the forefront of DNA synthesis applications.

Regional Insights

North America dominated the market and accounted for a 39.76% revenue share in 2023. The region experiences market growth due to heightened public awareness, robust medical facilities, and substantial R&D investments. In addition, the prevalence of chronic illnesses and substantial investments by market players in gene synthesis and gene therapy research amplify regional expansion, fostering a promising environment for further growth. Furthermore, the presence of key players in the market is expected to support regional expansion.

U.S. DNA Synthesis Market Trends

The U.S. DNA synthesis market has witnessed significant growth in recent years. Growth in the region can be attributed to the increasing demand for synthetic DNA & RNA sequences in various applications, such as research, diagnostics, and therapeutics. The competitive landscape of this market is characterized by a mix of established players and emerging companies striving to capture a share of the expanding market.

Europe DNA Synthesis Market Trends

DNA synthesis market in Europe was identified as a lucrative region in this industry. This is attributed to strong government support, advancements in research infrastructure, and the increased prevalence of chronic diseases & rising adoption of gene therapy.

UK DNA synthesis market is expected to grow over the forecast period due to robust research and innovation in genetic & molecular studies, coupled with supportive government initiatives and a strong healthcare infrastructure that fosters advancements in biomedical research. According to an article published in November 2023 by the Imperial College Healthcare NHS Trust, the UK's approval of gene editing therapy, specifically the CRISPR-based Casgevy, marks a milestone with potential implications for the UK DNA Synthesis market.

DNA synthesis market in France has a high burden of cancer which is also the leading cause of death. Oligonucleotides and genetic profiles are increasingly important in cancer diagnostics, including personalized medicine approaches, such as gene expression profiling and liquid biopsies. Moreover, cardiovascular diseases are another major health concern in France, and oligonucleotides & genetic profiles of individuals are being investigated for their potential in diagnosing & treating conditions, such as atherosclerosis & heart failure, propelling the demand for DNA synthesis.

Germany DNA synthesis market is expected to grow over the forecast period owing to Germany’s strong R&D landscape in diagnostics & therapeutics that harness the adoption of innovative therapies. Furthermore, the government in Germany is actively promoting the development of biotechnology and healthcare infrastructure. Initiatives such as “Industrie 4.0” and grants for R&D empower domestic players and attract foreign investments, impacting the DNA synthesis market positively.

Asia Pacific DNA Synthesis Market Trends

DNA synthesis market in Asia Pacific is anticipated to witness the fastest growth at a CAGR of 17.50% from 2024 to 2030 in the DNA synthesis market. The regional market is expected to be driven by the growing demand for synthetic DNA in research & diagnostics, the increasing prevalence of genetic diseases, and the rising need for personalized medicine.

China DNA synthesis market is expected to grow at the highest CAGR of 21.41% over the forecast period. The rise of CROs and the outsourcing of drug discovery & development activities by pharmaceutical & biotech companies are contributing to the market growth in China. Moreover, expansion plays a key role in this market. It involves investing in larger and more advanced synthesis facilities. For instance, in May 2023, GenScript expanded its oligonucleotide manufacturing facility in Jiangsu, China.

The DNA synthesis market in Japan is expected to witness significant growth over the forecast period. Japan has a significant aging population and a high focus on personalized medicine. Japan is a major player in scientific research, particularly in biotechnology and biopharmaceuticals. This research relies on oligonucleotides and gene expressions for various experiments and analyses, propelling the market growth.

India DNA synthesis market is anticipated to grow at a rapid rate over the forecast period. Due to the high birth rate, India has a high prevalence of genetic disorders due to various factors, such as consanguineous marriages and founder mutations.  The Indian government is actively promoting the development of biotechnology and healthcare infrastructure.  Moreover, the initiatives like “Make in India” and R&D grants empower domestic players and attract foreign investments, impacting the DNA synthesis market. For instance, in September 2019, the Department of Biotechnology (DBT) launched the Unique Methods of Management & Treatment of Inherited Disorders (UMMID) initiative in India to tackle inherited genetic diseases in newborn babies. These factors are expected to boost the market in India.

Middle East And Africa DNA Synthesis Market Trends

The DNA synthesis market in Middle East and Africa is projected to grow in near future due to the rising prevalence of chronic & infectious diseases, the growing incidence of genetic diseases, and the increased investments in the field of biotechnology & life sciences.

Saudi Arabia DNA synthesis market is expected to grow over the forecast period. The country has been investing in biotechnology and life sciences initiatives, including R&D. The growth of these initiatives is expected to drive the demand for DNA synthesis in various applications, such as genomics, diagnostics, and therapeutics. In addition, the growing incidence of genetic diseases and various government initiatives to combat them are projected to boost the market

DNA synthesis market in UAE is anticipated to witness growth over the forecast period due to the rapidly growing healthcare sector fueled by government investments, an increasing population, and rising disposable incomes. Moreover, there is a growing awareness of the benefits of genetic testing in the UAE, particularly for prenatal screening, cancer diagnosis, and personalized medicine. The UAE government is actively promoting the adoption of precision medicine, which tailors medical treatments to an individual’s genetic makeup. For instance, in June 2023, the Department of Health - Abu Dhabi (DoH), M42, and AbbVie signed a Memorandum of Understanding (MoU). It aimed to combine the expertise and resources of DoH, M42, & AbbVie to tailor personalized medicine & genomics solutions for individuals in Abu Dhabi.

Key DNA Synthesis Company Insights

Key players operating in the market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are playing a key role in propelling market growth.

Recent Developments

• In May 2024, Molecular Assemblies, Inc. initiated a Partnering Program aimed at granting licenses for the company’s Full Enzymatic Synthesis technology. Through this collaborative effort, limited participants will be provided with the company’s automated synthesis platform, any advancements or refinements to its FES platform, and the requisite licenses to conduct FES for research purposes within their facilities.  

• In November 2023, QIAGEN and Element Biosciences, Inc. partnered strategically to provide broad NGS workflows for the innovative sequencing platform Element AVITI System.

• In April 2023, Eurofins BioPharma Product Testing (Eurofins Scientific) completed a substantial expansion of its Stability Services offering at the Lancaster, PA, facility. This is anticipated to boost the demand for DNA synthesis production.

• In February 2023, Tecan and Element Biosciences collaborated to provide a benchtop NGS workflow with MagicPrep NGS. The product is AVITI System, an innovative DNA sequencing platform by Element Biosciences, Inc.

• In January 2022, Univercells made its entry into the synthetic biology space by acquiring the French DNA synthesis firm, SynHelix. SynHelix’s technology is based on the GMP production of large quantities of long DNA fragments. It has been presented as an alternative to DNA amplification in bacteria within the fields of synthetic biology, gene therapy, and diagnostics.

• In August 2020, Codex DNA (renamed to Telesis Bio Inc. in October 2022) launched the BioXp 3250 platform for synthetic biology workflow. The platform aims to accelerate the development of new biologics and vaccines. It allows researchers to generate large DNA fragments of up to 7kb at high speed without compromising accuracy.

• In January 2020, the U.S. Intelligence Advanced Research Projects Activity (IARPA) provided USD 23.0 million to DNA Script and its partners, including Illumina, for DNA-based data storage.

DNA Synthesis Market Report Scope

Global DNA Synthesis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global DNA synthesis market report based on product, length, application, end-use, and region.

• Service Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Oligonucleotide Synthesis

    • Standard Oligonucleotide Synthesis

    • Custom Oligonucleotide Synthesis

  • Gene Synthesis

    • Custom Gene Synthesis

    • Gene Library Synthesis

• Length Outlook (Revenue, USD Million, 2018 - 2030)

  • Oligonucleotide Synthesis

    • Less than 50 nt

    • 51-100 nt

    • 101-150 nt

    • More than 150 nt

  • Gene Synthesis

    • Less than 500 nt

    • 501-1000 nt

    • 1001-1500 nt

    • 1501-2000 nt

    • 2001-2500 nt

    • More than 2500 nt

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Research and Development

    • Oligonucleotide Synthesis

      • PCR

      • NGS

      • CRISPR

      • Cloning and Mutagenesis

      • Others

    • Gene Synthesis

      • Synthetic Biology

      • Vaccine Development

      • Genetic Engineering

      • Others

  • Diagnostics

  • Therapeutics

    • RNAi Therapies

    • Antisense Oligonucleotide-based Therapies

    • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biopharmaceutical and Diagnostics Companies

  • Academic and Research Institutes

  • Contract Research Organizations

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait